Dasatinib and quercetin for chemo-resistant triple negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding dasatinib and quercetin to your treatment can reverse resistance to chemotherapy in triple negative breast cancer that has spread or come back. It aims to help your body respond better to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have triple negative breast cancer (meaning your tumor does not have HER2, estrogen, or progesterone receptors) that has spread or is locally advanced.
- Your cancer must have gotten worse after chemotherapy for advanced breast cancer.
- You need to be able to perform daily activities without help (ECOG 0 or 1).
- Your liver, kidney, and blood counts must be in a good range based on tests within the last 2 weeks.
- If you could become pregnant, you must agree to avoid pregnancy or use effective birth control during the study.
- You must have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This trial tests a combination of a PD-L1 antibody (a type of immunotherapy) with a low-dose, continuous chemotherapy regimen called VEX for advanced triple-negative breast cancer that has spread to other parts of the body. It may be an option if you have had only one prior chemotherapy for metastatic disease and have already been treated with certain common chemo drugs.
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.